Chinook Therapeutics, Inc. KDNY
40.39 0.00 (+0.00%)
At closeAug 10, 2023, 4:00 PM EDT
40.30 Day range 40.51
52-week range unavailable
- Market cap
- 2.63B
- Revenue (ttm)
- 5.26M
- Shares out
- 67.05M
- Forward P/E
- -11.37
- Volume
- 3.28M
- Open
- 40.31
- Previous close
- 40.39
- Day's range
- 40.30 – 40.51
- Beta
- 0.68
- Analysts
- Buy
- Price target
- 39.30 (-2.7%)
- Earnings date
- Aug 7, 2023
No chart data for this range yet.
Key statistics
- Enterprise value
- 2.30B
- PEG ratio
- -1.36
- Price / sales
- 500.03
- Price / book
- 6.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -32.20%
- Free cash flow
- -84.44M
- Total cash
- 350.38M
- Total debt
- 38.26M
- Return on equity
- -51.56%
- Short % of float
- 5.44%
- 50-day average
- 29.15
- 200-day average
- 24.27
Analyst view
Consensus: buy
Buy
Price target (mean) 39.30 -2.7% downside
Now 40.39
- Target (low)
- 30.00
- Target (mean)
- 39.30
- Target (high)
- 47.00
Ratings (-1m) 12 12 buy · 0 hold · 0 sell
- Strong buy6
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2023
Expected Aug 7, 2023. Consensus EPS estimate -0.81.
Financials — quick view
KDNY Revenue — quarterly 1.01M
KDNY Net income — quarterly -66.94M
KDNY EPS — quarterly -0.94
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 7, 2023 | Jun 1, 2023 | -0.81 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.80 | — | — | — |
| Feb 27, 2023 | Dec 1, 2022 | -0.79 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -0.62 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -0.62 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.68 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 21, 2023 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Jun 14, 2023 | Evercore ISI Group | down | Outperform | In-Line |
| Jun 13, 2023 | Stifel | down | Buy | Hold |
| Jun 13, 2023 | SVB Leerink | down | Outperform | Market Perform |
| Jun 13, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 12, 2023 | Cantor Fitzgerald | down | Overweight | Neutral |
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- chinooktx.com
News
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm 
Novartis Completes Acquisition of Chinook Therapeutics 
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm 
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm 
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm 
Chief Scientific Officer Andrew King Sells 1,168 Shares of Chinook Therapeutics Inc (KDNY) 
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm 
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm 
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm 
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
Your note
Sign in to keep a note on KDNY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Conversion of Exercise of derivative security | May 25, 2023 | 3,300 |
| BJERKHOLT ERIC H | Chief Financial Officer | Sale | Feb 9, 2023 | 38,867 |
| DAVIS JEREL C | Director | Conversion of Exercise of derivative security | May 25, 2023 | 733,770 |
| DOBMEIER ERIC L | Chief Executive Officer | Sale | Apr 23, 2023 | 301,138 |
| GREENMAN WILLIAM MARINER | Director | Sale | May 29, 2023 | 23,643 |
| GRIFFIN MICHELLE RENEE | Director | Conversion of Exercise of derivative security | May 25, 2023 | 3,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 7.72% | 5,161,888 | 202.45M | Mar 30, 2023 |
| Frazier Life Sciences Management, L.P. | 6.50% | 4,345,559 | 170.43M | Mar 30, 2023 |
| Blackrock Inc. | 5.89% | 3,942,539 | 154.63M | Mar 30, 2023 |
| Deep Track Capital, LP | 4.49% | 3,000,000 | 117.66M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 4.26% | 2,847,835 | 111.69M | Mar 30, 2023 |
| State Street Corporation | 4.02% | 2,688,048 | 105.43M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.60% | 1,709,505 | 67.05M | Dec 30, 2022 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.24% | 1,476,666 | 57.91M | Feb 27, 2023 |
| iShares Russell 2000 ETF | 1.69% | 1,112,841 | 43.65M | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 0.91% | 602,215 | 23.62M | Dec 30, 2022 |
| iShares Russell 2000 Value ETF | 0.77% | 509,205 | 19.97M | Feb 27, 2023 |
| Federated Hermes Kaufmann Fund | 0.68% | 450,000 | 17.65M | Jan 30, 2023 |